• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 2
  3. Author

Online ISSN: 2515-8260

Volume9, Issue2

Comparison of efficacy of 1% 2-chloroprocaine with ilioinguinal and iliohypogastric nerve block versus 0.5% hyperbaric bupivacaine for spinal anaesthesia in patients undergoing caesarean section: A randomised clinical study

    Dr. Sneha Rajur, Dr. Bhagyashri V Kumbar, Dr. Faraz Ahmed, Dr. Madhu KP

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 2, Pages 1630-1637

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Caesarean sections are routinely done under spinal anaesthesia using 0.5% hyperbaric bupivacaine that has a long duration of action. As most of the caesarean sections are of short duration, we decided to compare 1% 2-chloroprocaine with routinely used bupivacaine as chloroprocaine has rapid onset of action, producing an excellent sensory and motor blockade. After ethical committee clearance and informed written consent, 70 uncomplicated singleton parturients of ASA I and II posted for elective caesarean section were randomised into chloroprocaine (CP) and bupivacaine (B) group of 35 each.
Onset of sensory block in group CP was 1.71±0.62min and in group B was 2.31±0.63min. Onset of motor block in group CP was 2.54±0.88min and in group B was 2.66±0.76min. Mean time for maximum sensory block in group CP was 12.77±3.52min and in group B was 22.34±6.46min and time for maximum motor block in group CP was 9.14±2.23min and in group B was 10.86±2.18min. Two segment regression time in group CP was 39.34±4.46min and in group B was 63.14±4.7min. Mean duration of sensory block in group CP was 2.08±0.25hr and in group B was 3.60±0.27hr and duration of motor block in group CP was 1.07±0.14hr and in group B was 3.42±0.41hr. VAS scores in first 6hrs were lesser in group CP than group B. Onset, maximum time, duration of sensory and motor block were lower in group CP than group B. hemodynamic parameters were comparable between the groups with no side effects.
Keywords:
    Chloroprocaine Bupivacaine caesarean section
  • PDF (548 K)
  • XML
(2022). Comparison of efficacy of 1% 2-chloroprocaine with ilioinguinal and iliohypogastric nerve block versus 0.5% hyperbaric bupivacaine for spinal anaesthesia in patients undergoing caesarean section: A randomised clinical study. European Journal of Molecular & Clinical Medicine, 9(2), 1630-1637.
Dr. Sneha Rajur, Dr. Bhagyashri V Kumbar, Dr. Faraz Ahmed, Dr. Madhu KP. "Comparison of efficacy of 1% 2-chloroprocaine with ilioinguinal and iliohypogastric nerve block versus 0.5% hyperbaric bupivacaine for spinal anaesthesia in patients undergoing caesarean section: A randomised clinical study". European Journal of Molecular & Clinical Medicine, 9, 2, 2022, 1630-1637.
(2022). 'Comparison of efficacy of 1% 2-chloroprocaine with ilioinguinal and iliohypogastric nerve block versus 0.5% hyperbaric bupivacaine for spinal anaesthesia in patients undergoing caesarean section: A randomised clinical study', European Journal of Molecular & Clinical Medicine, 9(2), pp. 1630-1637.
Comparison of efficacy of 1% 2-chloroprocaine with ilioinguinal and iliohypogastric nerve block versus 0.5% hyperbaric bupivacaine for spinal anaesthesia in patients undergoing caesarean section: A randomised clinical study. European Journal of Molecular & Clinical Medicine, 2022; 9(2): 1630-1637.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 48
  • PDF Download: 74
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus